AEON Biopharma, Inc. (AEON)
- Previous Close
1.6600 - Open
1.6800 - Bid 1.6500 x 2900
- Ask 1.8300 x 1100
- Day's Range
1.6200 - 1.7400 - 52 Week Range
1.3800 - 17.1700 - Volume
71,027 - Avg. Volume
95,183 - Market Cap (intraday)
67.094M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
www.aeonbiopharma.comRecent News: AEON
Performance Overview: AEON
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AEON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AEON
Valuation Measures
Market Cap
67.09M
Enterprise Value
62.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-374.77%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.63M
Diluted EPS (ttm)
-0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.48M
Research Analysis: AEON
Company Insights: AEON
AEON does not have Company Insights